Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brown-Forman Corporation Class B (BF.B) vs Merck & Co., Inc. (MRK) Price & Performance

Brown-Forman Corporation Class BTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Brown-Forman Corporation Class B vs Merck & Co., Inc. — how do they compare? Brown-Forman Corporation Class B trades at $29.9, while Merck & Co., Inc. trades at $130.23 (market cap $323.00B). The key difference: Merck & Co., Inc. pays a 2.6% dividend while Brown-Forman Corporation Class B pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Brown-Forman Corporation Class B nearer its low. Which is the better fit depends on your goals.

BF.BMRK
Sector
Consumer StaplesHealth
52-Week High
$31.26$131.84
52-Week Low
$22.80$77.60
Market Cap
$323.00B
Enterprise Value
$369.77B
Dividend Yield
2.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Brown-Forman Corporation Class B

BF.B trades at $28.52, up 0.88% today, with a bullish technical signal from moving averages and strong trend strength (ADX). Earnings have beaten estimates in three of the last four quarters, with Q2 2024 EPS of $0.48 exceeding the $0.46 forecast. The stock faces mixed analyst sentiment but shows consistent fundamental performance.

The outlook is cautiously optimistic given recent earnings strength, though limited analyst coverage and mixed ratings suggest uncertainty. Key risks include execution challenges and market volatility. Upside potential hinges on sustained earnings growth and broader market conditions.

Merck & Co., Inc.

Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.

The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Brown-Forman Corporation Class B

Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.

Read more on BF.B

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK